Medizinische Universität Graz - Research portal
Selected Publication:
Tinchon, C; Auner, HW; Beham-Schmid, C; Aberle, SW; Sill, H; Linkesch, W.
Symptomatic Epstein-Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti-CD20 antibody rituximab.
EUR J HAEMATOL 2002 69: 50-53.
Doi: 10.1034%2Fj.1600-0609.2002.02740.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Beham-Schmid Christine
- Linkesch Werner
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein-Barr virus reactivation.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antibodies, Monoclonal - immunology
- Antigens, CD20 - immunology
- Antineoplastic Agents - therapeutic use
- Herpesvirus 4, Human - isolation and purification
- Humans - isolation and purification
- Leukemia, Myeloid - drug therapy
- Lymphocyte Depletion - drug therapy
- Male - drug therapy
- Virus Activation - drug therapy
- Find related publications in this database (Keywords)
- Epstein-Barr virus
- rituximab
- fludarabine
- acute myeloid leukaemia